Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
7.49
-0.18 (-2.28%)
Dec 27, 2024, 2:56 PM EST - Market open
Recursion Pharmaceuticals Analyst Ratings
Total Analysts
5
Consensus Rating
Buy
Price Target
$9.25
Upside
+23.58%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +46.96% | Dec 11, 2024 |
| Needham | Needham | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +46.96% | Nov 20, 2024 |
| Needham | Needham | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +46.96% | Nov 7, 2024 |
| Needham | Needham | Strong Buy Maintains $16 → $11 | Strong Buy | Maintains | $16 → $11 | +46.96% | Sep 4, 2024 |
| Jefferies | Jefferies | Hold Maintains $8 → $6 | Hold | Maintains | $8 → $6 | -19.84% | Sep 3, 2024 |
| Leerink Partners | Leerink Partners | Hold Maintains $9 → $8 | Hold | Maintains | $9 → $8 | +6.88% | Sep 3, 2024 |
| Needham | Needham | Strong Buy Maintains $17 → $16 | Strong Buy | Maintains | $17 → $16 | +113.76% | Aug 9, 2024 |
| Keybanc | Keybanc | Buy Maintains $16 → $12 | Buy | Maintains | $16 → $12 | +60.32% | Jul 11, 2024 |
| Needham | Needham | Strong Buy Reiterates $17 | Strong Buy | Reiterates | $17 | +127.12% | Jun 25, 2024 |
| Needham | Needham | Strong Buy Reiterates $17 | Strong Buy | Reiterates | $17 | +127.12% | May 10, 2024 |
| Needham | Needham | Strong Buy Reiterates $17 | Strong Buy | Reiterates | $17 | +127.12% | Apr 9, 2024 |
| Keybanc | Keybanc | Buy Maintains $15 → $16 | Buy | Maintains | $15 → $16 | +113.76% | Mar 4, 2024 |
| Needham | Needham | Strong Buy Maintains $15 → $17 | Strong Buy | Maintains | $15 → $17 | +127.12% | Feb 28, 2024 |
| TD Cowen | TD Cowen | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Jan 26, 2024 |
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +100.40% | Jan 17, 2024 |
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +100.40% | Jan 16, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.